

PUBLISHED BY PORTLAND PRESS ON BEHALF OF  
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY

© The Medical Research Society and the Biochemical Society 1996  
ISSN 0143-5221

*Printed in Great Britain by Bell and Bain Limited, Glasgow*

## Volume 90

### AUTHOR INDEX

- Abdel-Rahman, T.A. 485-492  
Abe, K. 31-36, 55-60  
Aihara, A. 55-60  
Al-Ani, M. 235-241  
Aller, M.-A. 321-322  
Ameshima, S. 517-523  
Ang, B.C. 73-75  
Arias, J. 321-322  
Arner, P. 243-253, 453-456  
Ashby, M.J. 37-46
- Barnes, P.J. 301-306  
Bartlett, K. 307-313  
Bavington, C. 61-71  
Bech, J.N. 87-89  
Belcher, P.R. 363-368  
Bennett, J.L. 183-187  
Bennett, M.A. 21-29  
Bergelson, B.A. 261-268  
Bernardi, L. 345-355  
Berre, J. 105-111  
Bettany, G.E.A. 73-75  
Bhaskar, A. 255-260  
Bing, C. 499-505  
Blum, M. 379-384  
Boulton, A.J.M. 183-187  
Broughton Pipkin, F. 499-505  
Burnett, J.C. 357-362  
Buxton, B.F. 91-96
- Cabili, S. 379-384  
Cacabelos, R. 153-156  
Calciati, A. 345-355  
Capdevila, A. 81-85  
Carr, P. 507-510  
Chan, S.-H. 127-133  
Chang, C.-J. 127-133  
Chen, J.R. 91-96  
Cheng, C. 97-103  
Chow, N.-H. 127-133  
Christensen, N.J. 269-276  
Clark, A.F. 435-446  
Clark, M.L. 409-415  
Coats, A.J.S. 345-355  
Collins, K.J. 485-492  
Coote, J.H. 235-241
- Coppack, S.W. 409-415  
Corry, D.B. 2-8  
Court-Payen, M. 269-276  
Cowley, A.J. 473-483  
Csernihovsky, T. 379-384
- Davenport, A.P. 37-46  
De Backer, D. 105-111  
De Blaauw, I. 457-466  
De Jong, P.E. 393-401  
De Landázuri, M.O. 148-153  
De Zeeuw, D. 393-401  
Deutz, N.E.P. 457-466  
Devynck, M.-A. 403-407  
Diez, J.J. 169-171  
Dodd, C.M. 417-425  
Donnelly, A.E. 119-125  
Doré, C.J. 485-492  
Douglas, J.T. 183-187  
Drake-Holland, A.J. 363-368
- Easton, J.C. 485-492  
Eaton, S. 307-313  
Edwards, R.H.T. 295-300, 467-472  
Egido, J. 161-162  
Ellis, C.C. 2-8  
Evans, T.W. 47-54, 173-182, 301-306
- Fahal, I. 295-300  
Färkkilä, M.A. 315-319  
Feihl, F. 369-377  
Fisher, R.M. 409-415  
Fleisher, L.A. 97-103  
Floras, J.S. 189-195  
Fogh-Andersen, N. 511-515  
Ford, G.A. 493-497  
Forkins, A.S. 235-241  
Forni, L.G. 507-510  
Frank, S.M. 97-103  
Frayn, K.N. 243-253, 409-415, 453-456  
Fuller, B.J. 135-141
- Garrard, C.S. 345-355
- Garrido, E. 81-85  
Georgiannos, S.N. 73-75  
Ghahary, A. 417-425  
Giles, S.L. 453-456  
Goka, J. 77-80  
Goldstein, D.S. 337-343  
Gómez-Pan, A. 169-171  
Gorodetsky, E. 287-293  
Gosling, R.G. 143-144, 433-434  
Green, C.J. 135-141  
Griffiths, M.J.D. 47-54  
Gutteridge, J.M.C. 47-54
- Halliday, D. 73-75  
Hamada, M. 197-204  
Hannedouche, T.P. 205-213  
Heigenhauser, G.J.F. 323-335  
Heller, J. 385-391  
Helliwell, T.R. 467-472  
Herrero, J.I. 162-167  
Hidalgo, M.A. 135-141  
Higgs, C.M.B. 227-234  
Hilton, P.J. 507-510  
Hiwada, K. 197-204  
Hopkins, K.D. 143-144, 433-434  
Horacek, V. 385-391  
Høst, U. 269-276  
Hughes, R.D. 77-80  
Humphreys, S.M. 409-415  
Hurni, J.-M. 369-377  
Hynd, J.W. 363-368
- Iaina, A. 379-384  
Imai, Y. 55-60  
Ishizaki, T. 517-523  
Ison, J. 485-492
- Jaap, A.J. 113-117  
Jackson, A.A. 215-225  
Jackson, M.J. 295-300, 467-472  
Jacobs, M.-C. 337-343  
Javierre, C. 81-85  
Jobanputra, P. 61-71  
Johnson, I.R. 499-505  
Johnston, C.I. 31-36  
Jones, N.L. 323-335

- Kairemo, K.J. 315–319  
 Kalman, R. 287–293  
 Kanazawa, M. 31–36  
 Kasai, Y. 55–60  
 Kato, J. 55–60  
 Kawakami, H. 197–204  
 Keane, H.M. 77–80  
 Kearney, M.T. 473–483  
 Kelbaek, H. 269–276  
 Kinoshita, M. 357–362  
 Kishi, Y. 517–523  
 Kohzuki, M. 31–36  
 Kok, W.E.M. 144–146  
 Kramer, H.J. 385–391  
 Kuc, R.E. 37–46  
  
 Lacour, B. 205–213  
 Laszlo, G. 227–234  
 Lehmann, E.D. 143–144, 433–434  
 Lenders, J.W.M. 337–343  
 Leyssac, P.P. 511–515  
 Liaudet, L. 369–377  
 Liderth, S.A. 183–187  
 Lin, J.S.-N. 127–133  
 Liu, J.J. 91–96  
 Liu, S.F. 301–306  
 Logan, A.G. 189–195  
 Lorente, L. 321–322  
 Lorenzen, T. 269–276  
  
 Macdonald, I.A. 473–483  
 MacLennan, P.A. 467–472  
 Mahdy, Z.A. 493–497  
 Mann, D.J. 135–141  
 Maree, A. 379–384  
 Markert, M. 369–377  
 Martinez, F. 205–213  
 Mato, J.M. 147–148  
 Matsuda, Y. 357–362  
 Matsukawa, T. 97–103  
 McArdle, A. 295–300, 467–472  
 McArdle, F. 295–300  
 Meakins, T.S. 215–225  
 Melot, C. 105–111  
 Messent, M. 47–54  
 Miettinen, T.A. 315–319  
 Millanvoye-Van Brussel, E. 403–407  
 Miller, J.A. 189–195  
 Miyabo, S. 517–523  
 Mohan, R. 255–260  
 Monserrat, E. 167–169  
 Moraine, J.J. 105–111  
 Mullins, J.J. 435–446  
 Munakata, M. 55–60  
  
 Nakai, T. 517–523  
 Natov, S. 205–213  
 Navarro-López, F. 156–158  
 Navis, G. 393–401  
 Neusser, M. 9–12  
 Newton, R. 301–306  
 Nielsen, C.B. 87–89  
 Nishiyama, A. 55–60  
 Noble, M.I.M. 363–368  
 Nuki, G. 61–71  
  
 O'Reilly, G. 37–46  
 Ohkubo, T. 55–60  
 Okayama, H. 197–204  
 Olsen, N.V. 511–515  
 Onodera, N. 55–60  
  
 Page, S.F. 295–300  
 Pedersen, E.B. 87–89  
 Pedersen-Bjergaard, U. 269–276  
 Peer, G. 379–384  
 Perret, C. 369–377  
 Perry, A.J. 473–483  
 Peters, R.J.G. 144–146  
 Peters, N.S. 447–452  
 Plumpton, C. 37–46  
 Pointon, J.J. 409–415  
 Powell-Tuck, J. 73–75  
 Prieto, J. 162–167  
 Pujol, J. 81–85  
  
 Quinlan, G.J. 47–54  
  
 Raasch, R.H. 427–431  
 Radaelli, A. 345–355  
 Rahemtulla, F. 417–425  
 Rasmusen, H. 269–276  
 Ravell, C.L. 453–456  
 Record, C.O. 307–313  
 Reeder, M. 345–355  
 Robson, S.C. 493–497  
 Rodriguez-Arno, J. 169–171  
 Rosset, A. 369–377  
 Rozman, C. 167–169  
 Ruilope, L.M. 159–160  
 Ruocco, N.A. 261–268  
  
 Sacco, P. 485–492  
 Sair, M. 173–182  
 Salter, D.M. 61–71  
 Samra, J.S. 453–456  
 Sasaki, F. 517–523  
 Sato, T. 31–36  
 Satoh, H. 55–60  
 Saxton, J.M. 119–125  
  
 Schmitt, F. 205–213  
 Scott, P.G. 417–425  
 Scullard, T.F. 277–285  
 Segura, R. 81–85  
 Sekino, M. 55–60  
 Sessler, D.I. 97–103  
 Shanmugasundaram, K.R. 255–260  
 Sharp, M.G.F. 435–446  
 Sheron, N. 77–80  
 Shore, A.C. 113–117  
 Silverberg, D.S. 379–384  
 Sipkema, P. 144–146  
 Skorecki, K.L. 189–195  
 Sleight, P. 345–355  
 Smits, P. 337–343  
 Solda, P.L. 345–355  
 Strandberg, T.A. 315–319  
 Strandgaard, S. 511–515  
 Streeten, D.H.P. 277–285  
 Stubbs, T.A. 473–483  
 Sundaram, R.K. 255–260  
 Supaporn, T. 357–362  
  
 Taavitsainen, M.J. 315–319  
 Tepel, M. 9–12  
 Thien, T. 337–343  
 Thurston, H. 21–29  
 Tooke, J.E. 113–117  
 Townend, J.N. 235–241  
 Treacher, D.F. 507–510  
 Tredget, E.E. 417–425  
 Tsuji, I. 55–60  
 Tsutsumi, E. 31–36  
 Tuck, M.L. 2–8  
 Tzai, T.-S. 127–133  
  
 Ulshen, M.H. 427–431  
  
 Van Goor, H. 393–401  
 Vanfraechem, J. 105–111  
 Vannier, C.A. 97–103  
 Ventura, J.L.I. 81–85  
 Veves, A. 183–187  
 Vijayalingam, S. 255–260  
 Vincent, J.-L. 105–111  
 Viswanathan, M. 255–260  
 Von Meyenfeldt, M.F. 457–466  
  
 Wapstra, F.H. 393–401  
 Watanabe, N. 55–60  
 Wei, C.-M. 357–362  
 Weinstock, M. 287–293  
 Wennberg, P.W. 357–362

- Willemsen, J.J. 337–343  
Williams, C.M. 243–253  
Williams, R. 77–80  
Winlove, C.P. 173–182  
Wollman, Y. 379–384  
Wright, D.A. 507–510  
Wright, M. 61–71
- Yasujima, M. 31–36  
Yeh, T.-M. 127–133  
Yoshida, K. 31–36  
Yoshino, H. 55–60  
Young, M.J. 183–187  
Yu, T.-K. 261–268  
Yudkin, J.S. 13–19
- Zaidi, K.F. 13–19  
Zaitoun, A.M. 307–313  
Zhu, Z. 9–12  
Zidek, W. 9–12  
Zinman, B. 189–195

## SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Reviews.

- Acetylcholine  
Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
- Acid-base control  
muscle, exercise 323–335\*
- Acute tobacco smoking  
probucol 517–523
- Acute renal failure  
lactate metabolism, haemofiltration 507–510
- Adipose tissue  
carbohydrate metabolism, insulin resistance 409–415  
interstitial glycerol 453–456
- Adrenaline  
baroreflex activity, lower body negative pressure 337–343
- Adrenergic agents  
oxygen consumption/delivery relationship 105–111
- Adriamycin  
angiotensin-converting enzyme inhibition, proteinuria 393–401
- Ageing  
facial cooling, cardiorespiratory reflexes 485–492
- Alcohol  
fatty liver,  $\beta$ -oxidation 307–313
- Altitude  
brain damage, Sherpas 81–85
- Amino acid turnover  
muscle, starvation 457–466
- Ammonia  
protein turnover, bed rest 73–75
- Angiogenesis  
basic fibroblast growth factor, urothelial carcinoma 127–133
- Angiotensin I-receptor blockade  
renal effects 205–213
- Angiotensin receptors  
myometrium, pregnancy 499–505
- Angiotensin-converting enzyme inhibitors  
resistance artery, endothelium-dependent relaxation 21–29
- Angiotensin-converting enzyme inhibition  
nephrosis, proteinuria 393–401  
renal effects 205–213
- Antioxidant enzymes  
lipid peroxidation, diabetes 255–260
- Antioxidant vitamins  
lipid peroxidation, diabetes 255–260
- L-Arginine  
nitric oxide, diabetes mellitus 379–384
- Arrhythmias  
gap junctions, myocardium 447–452
- Arteries  
endothelin B receptor agonists and antagonists 91–96
- Articular cartilage  
membrane potential, ion channels 61–71
- Asthma  
perception, treatment 227–234
- Atrial natriuretic peptide  
gene expression, renovascular hypertension 197–204  
heart failure, diuretics 31–36  
mean blood pressure, epoprostenol 87–89
- Autonomic insufficiency  
orthostatic intolerance, venous pooling 277–285
- Autonomic tone  
skin microcirculation 345–355
- Baroreflex activity  
catecholamines, lower body negative pressure 337–343  
skin microcirculation 345–355
- Baroreflex sensitivity  
renal nerves, hypertension 287–293
- Basic fibroblast growth factor  
inflammation, urothelial carcinoma 127–133

- Beclomethasone**  
 asthma, perception 227–234
- Bed rest**  
 protein turnover, urea 73–75
- Big endothelin**  
 immunochemistry, human endocardial  
 endothelial cells 37–46
- Bile acid malabsorption**  
 lathosterol, <sup>75</sup>SeHCAT test 315–319
- Blood**  
 carbon dioxide, exercise 323–335\*
- Blood flow**  
 autonomic tone, skin 345–355  
 meal composition 269–276
- Blood pressure**  
 lisinopril, angiotensin-converting enzyme  
 inhibition 393–401  
 seasonal variation 55–60
- Blood pressure regulation**  
 gene targeting 435–446\*
- Bradykinin**  
 Goldblatt hypertension, angiotensin-converting  
 enzyme inhibitors 21–29
- Brain damage**  
 Sherpas, magnetic resonance 81–85
- Brain natriuretic peptide**  
 gene expression, renovascular  
 hypertension 197–204
- Breath-holding**  
 facial cooling, ageing 485–492
- Bronchoconstriction**  
 perception, treatment 227–234
- Buffering capacity**  
 platelets, diabetes 13–19
- Burns**  
 wound healing, proteoglycans 417–425
- Calcium**  
 vascular smooth muscle, ouabain 9–12
- L-Canavanine**  
 nitric oxide synthase, endotoxaemia 369–377
- Canine kidney**  
 glomerular haemodynamics,  
 endothelin-1 385–391
- Capillary filtration coefficient**  
 diabetes, microangiopathy 113–117
- Carbohydrate**  
 postprandial haemodynamics 269–276
- Carbohydrate meal**  
 haemodynamics, cardiac transplant 473–483
- Carbohydrate metabolism**  
 insulin resistance 409–415
- Carbon dioxide**  
 metabolism, exercise 323–335\*
- Cardiac output**  
 meal composition 269–276
- Cardiac transplant**  
 postprandial haemodynamics 473–483
- Cardiac vagus**  
 facial cooling, ageing 485–492
- Cardiology**  
 Spain 156–158
- Cardiomyocytes**  
 phospholipase A<sub>2</sub>, hypertension 403–407
- Cardiopulmonary baroreceptors**  
 catecholamines, lower body negative  
 pressure 337–343
- Cardiorespiratory reflexes**  
 facial cooling, ageing 485–492
- Cartilage**  
 membrane potential, ion channels 61–71
- Catecholamines**  
 baroreflex activity, lower body negative  
 pressure 337–343
- Cell attachment**  
 endothelial cells, organ preservation 135–141
- Cerebral hypoxia**  
 Sherpas, magnetic resonance 81–85
- Chlorothiazide**  
 renin, heart failure 31–36
- Cholesterol**  
 coronary vascular reserve, endothelium 261–268
- Cholesterol synthesis**  
 bile acid synthesis, lathosterol 315–319
- Chondrocytes**  
 mechanoreceptors, ion channels 61–71
- Chronic fatigue syndrome**  
 enterovirus, polymerase chain reaction 295–300
- Chronic renal failure**  
 sodium, potassium pump 3–8
- Climbing**  
 brain damage, Sherpas 81–85
- Clinical research**  
 progress in Spain 147–171
- Coagulation**  
 thrombin, recombinant hirudin 363–368
- Compliance**  
 definitions 143–146, 433–434
- Connexin43**  
 arrhythmias, gap junctions 447–452
- Coronary blood flow**  
 natriuretic peptides 357–362
- Coronary heart disease**  
 fatty acids 243–253\*
- Coronary thrombosis**  
 thrombin, recombinant hirudin 363–368
- Coronary vascular reserve**  
 endothelium, hypercholesterolaemia 261–268

- Creatine kinase  
  muscle damage, chronic fatigue syndrome 295–300
- Cromoglycate  
  asthma, perception 227–234
- Cyclo-oxygenase  
  gene expression, endotoxaemia 301–306
- Cytokines  
  fulminant hepatic failure 77–80
- Daytime length  
  blood pressure 55–60
- Definitions  
  compliance 433–434
- Dermatan sulphate  
  burns, wound healing 417–425
- Diabetes  
  antioxidant status, lipid peroxidation 255–260  
  fatty acids, coronary heart disease 243–253\*  
  microalbuminuria, sodium/hydrogen exchange rate 13–19  
  microangiopathy, vascular permeability 113–117  
  nitric oxide, L-arginine 379–384  
  peripheral neuropathy, rheology 183–187  
  plasma renin activity, hyperglycaemia 189–195
- Diuretics  
  renin, heart failure 31–36
- Dobutamine  
  oxygen consumption/delivery relationship 105–111
- Dopamine  
  renal tubular function, lithium clearance 511–515
- Doxorubicin  
  angiotensin-converting enzyme inhibition, proteinuria 393–401
- Eating  
  haemodynamic effects 269–276
- Eccentric exercise  
  strength loss, muscle damage 119–125
- Elastase inhibitory capacity  
  acute tobacco smoking, probucol 517–523
- Embryonic stem cells  
  gene targeting 435–446\*
- Endocardial endothelial cells  
  endothelin, reverse transcriptase–polymerase chain reaction 37–46
- Endocrinology  
  Spain 169–171
- Endogenous lithium clearance  
  dopamine, renal tubular function 511–515
- Endogenous natriuretic peptides  
  coronary blood flow 357–362
- Endothelial cells  
  permeability, organ preservation 135–141
- Endothelin  
  reverse transcriptase–polymerase chain reaction, human endocardial endothelial cells 37–46
- Endothelin B receptor agonists  
  arteries 91–96
- Endothelin B receptor antagonists  
  arteries 91–96
- Endothelin receptor subtypes  
  arteries 91–96
- Endothelin-1  
  glomerular haemodynamics 385–391
- Endothelium  
  coronary vascular reserve, hypercholesterolaemia 261–268
- Endothelium-dependent relaxation  
  Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
- Endotoxaemia  
  cyclo-oxygenase, gene expression 301–306  
  nitric oxide synthase, L-canavanine 369–377
- Enterovirus  
  chronic fatigue syndrome, polymerase chain reaction 295–300
- Epidermal growth factor  
  mucosal mass, starvation 427–431
- Epoprostenol  
  atrial natriuretic peptide, mean blood pressure 87–89
- Exercise  
  carbon dioxide, metabolism 323–335\*  
  protein turnover, bed rest 73–75
- Exogenous lithium clearance  
  dopamine, renal tubular function 511–515
- Facial cooling  
  cardiorespiratory reflexes, ageing 485–492
- Faecal bile acid excretion  
  lathosterol, <sup>75</sup>SeHCAT test 315–319
- Fasting  
  muscle necrosis, *mdx* mouse 467–472
- Fat  
  postprandial haemodynamics 269–276
- Fat meal  
  haemodynamics, cardiac transplant 473–483
- Fatty acids  
  coronary heart disease 243–253\*
- Ferroxidase activity  
  acute tobacco smoking, probucol 517–523
- Forearm  
  carbohydrate metabolism, insulin resistance 409–415
- Forearm blood flow  
  hyperglycaemia, diabetes 189–195

- Fractional dextran clearance  
renin-angiotensin system inhibition 205-213
- Fulminant hepatic failure  
tumour necrosis factor soluble receptor 77-80
- Gap junctions  
arrhythmias, myocardium 447-452
- Gene expression  
cyclo-oxygenase, endotoxaemia 301-306  
natriuretic peptides, renovascular hypertension 197-204
- Gene targeting  
blood pressure regulation 435-446\*
- Genetic hypertension  
phospholipase A<sub>2</sub>, cardiomyocytes 403-407
- Glomerular filtration rate  
hyperglycaemia, diabetes 189-195  
renin-angiotensin system inhibition 205-213
- Glomerular haemodynamics  
endothelin-1 385-391
- Glomerular ultrafiltration  
endothelin-1 385-391
- Glomerulosclerosis  
angiotensin-converting enzyme inhibition 393-401
- Glucose uptake  
insulin resistance 409-415
- Glutathione  
acute tobacco smoking, probucol 517-523
- Glycerol  
muscle, adipose tissue 453-456
- Glycine  
protein turnover, bed rest 73-75
- Guanylyl cyclase  
endogenous natriuretic peptides 357-362
- Haematology  
Spain 167-169
- Haemodynamic effects  
meal composition 269-276
- Haemofiltration  
lactate metabolism, acute renal failure 507-510
- Heart failure  
renin, diuretics 31-36  
vascular endothelium, psycho-neuro-immune-endocrine system 321-322
- Heart rate  
atrial natriuretic peptide, epoprostenol 87-89
- Heart rate variability  
respiratory sinus arrhythmia 227-234  
skin microcirculation, autonomic tone 345-355  
spectral analysis, thermoregulation 97-103
- Hepatology  
Spain 162-167
- Hirudin  
thrombin, intracoronary thrombosis 363-368
- Homologous recombination  
gene targeting 435-446\*
- Host-tumour interaction  
basic fibroblast growth factor, urothelial carcinoma 127-133
- Hypercholesterolaemia  
coronary vascular reserve, endothelium 261-268
- Hyperglycaemia  
plasma renin activity, diabetes 189-195
- Hypertension  
baroreflex sensitivity, renal nerves 287-293  
phospholipase A<sub>2</sub>, cardiomyocytes 403-407  
resistance artery, angiotensin-converting enzyme inhibitors 21-29  
sodium/hydrogen exchange rate, diabetes 13-19  
Spain 159-160
- Hypertension research  
gene targeting 435-446\*
- Hypertrophic scars  
wound healing, proteoglycans 417-425
- Hypertrophy  
arrhythmias, gap junctions 447-452
- Hypothermia  
heart rate variability, spectral analysis 97-103
- Hypoxia  
Sherpas, magnetic resonance 81-85
- Hypoxic pulmonary vasoconstriction  
lung oedema, reactive oxygen species scavengers 47-54
- Ileal resection  
bile acid malabsorption 315-319
- Immunological research  
Spain 148-153
- Indoor temperature  
blood pressure 55-60
- Inducible nitric oxide synthase  
endotoxaemia, L-canavanine 369-377
- Inflammation  
basic fibroblast growth factor, urothelial carcinoma 127-133
- Infra-red photoplethysmography  
skin microcirculation, autonomic tone 345-355
- Insulin resistance  
carbohydrate metabolism 409-415  
fatty acids, coronary heart disease 243-253\*
- Interstitial glycerol  
muscle, adipose tissue 453-456
- Ischaemia  
arrhythmias, gap junctions 447-452
- Ischaemia-reperfusion injury  
hypoxic pulmonary vasoconstriction, reactive oxygen species scavengers 47-54



- Kidney function  
dopamine, lithium clearance 511–515
- Lactate metabolism  
haemofiltration, acute renal failure 507–510  
insulin resistance 409–415
- Lactic acidosis  
haemofiltration, acute renal failure 507–510
- Lathosterol  
<sup>75</sup>SeHCAAT test, bile acid  
malabsorption 315–319
- Lipid peroxide  
acute tobacco smoking, probucol 517–523
- Lipid peroxidation  
antioxidant status, diabetes 255–260
- Lipolysis  
adipose tissue 453–456
- Lipopolysaccharide  
cyclo-oxygenase, gene expression 301–306
- Lisinopril  
angiotensin-converting enzyme inhibition,  
nephrosis 393–401
- Lithium clearance  
dopamine, renal tubular function 511–515  
renin–angiotensin system inhibition 205–213
- Liver  
alcohol,  $\beta$ -oxidation 307–313
- Liver failure  
tumour necrosis factor soluble receptor 77–80
- Lower body negative pressure  
baroreflex activity, catecholamines 337–343  
facial cooling, ageing 485–492
- Luminal epidermal growth factor  
mucosal mass, starvation 427–431
- Lung oedema  
hypoxic pulmonary vasoconstriction, reactive  
oxygen species scavengers 47–54
- Mature scars  
wound healing, proteoglycans 417–425
- Mdx* mouse  
muscle necrosis, fasting 467–472
- Meal composition  
haemodynamic effects 269–276
- Mean blood pressure  
atrial natriuretic peptide, epoprostenol 87–89
- Membrane transport  
amino acids, starvation 457–466
- Menstrual cycle  
angiotensin receptors, myometrium 499–505
- Metabolism  
carbon dioxide, exercise 323–335\*
- Microalbuminuria  
diabetes, vascular permeability 113–117  
sodium/hydrogen exchange rate, diabetes 13–19
- Microangiopathy  
diabetes, vascular permeability 113–117
- Microcirculation  
sepsis 173–182\*
- Microvascular disease  
rheology, peripheral neuropathy 183–187
- Mitochondria  
muscle, chronic fatigue syndrome 295–300
- Monolayer continuity  
endothelial cells, organ preservation 135–141
- N<sup>G</sup>*-monomethyl-L-arginine  
pregnancy 493–497
- Mouse embryonic stem cells  
gene targeting 435–446\*
- Mucosal mass  
epidermal growth factor, starvation 427–431
- Muscle pain  
virus infection, chronic fatigue  
syndrome 295–300
- Muscle  
carbohydrate metabolism, insulin  
resistance 409–415  
carbon dioxide, exercise 323–335\*  
interstitial glycerol 453–456  
protein turnover, starvation 457–466
- Muscle damage  
strength loss, eccentric exercise 119–125
- Muscle necrosis  
fasting, *mdx* mouse 467–472
- Muscular dystrophy  
fasting, *mdx* mouse 467–472
- Myocardium  
arrhythmias, gap junctions 447–452
- Myometrium  
angiotensin receptors, pregnancy 499–505
- Natriuretic peptides  
gene expression, renovascular  
hypertension 197–204
- Natriuretic peptide receptor antagonist  
coronary blood flow 357–362
- Necrosis  
fasting, *mdx* mouse 467–472
- Nephrology  
Spain 161–162
- Nephrosis  
angiotensin-converting enzyme inhibition,  
proteinuria 393–401
- Neuroscience  
Spain 153–156
- Nitrate  
diabetes mellitus 379–384
- Nitric oxide  
L-arginine, diabetes mellitus 379–384  
pregnancy 493–497

- Nitric oxide synthase  
  endotoxaemia, L-canavanine 369–377  
  gene expression, endotoxaemia 301–306
- Nitric oxide synthase inhibitor  
  diabetes mellitus 379–384
- Nitrite  
  diabetes mellitus 379–384
- Nitroprusside  
  oxygen consumption/delivery  
  relationship 105–111
- Non-essential nitrogen  
  protein requirements 215–225
- Non-esterified fatty acids  
  coronary heart disease 243–253\*
- Noradrenaline  
  baroreflex activity, lower body negative  
  pressure 337–343
- Obesity  
  fatty acids, coronary heart disease 243–253\*
- Organ preservation  
  endothelial cells, permeability 135–141
- Orthostatic hypotension  
  autonomic insufficiency, venous  
  pooling 277–285
- Orthostatic tachycardia  
  autonomic insufficiency, venous  
  pooling 277–285
- $\beta$ -Oxidation  
  fatty liver, alcohol 307–313
- Ouabain  
  calcium, vascular smooth muscle 9–12
- Outdoor temperature  
  blood pressure 55–60
- Oxygen uptake  
  dobutamine, nitroprusside 105–111
- Peak expiratory flow  
  asthma, perception 227–234
- Perception  
  asthma, treatment 227–234
- Peripheral neuropathy  
  rheological and microvascular  
  parameters 183–187
- Permeability  
  endothelial cells, organ preservation 135–141
- Phenylalanine turnover  
  muscle, starvation 457–466
- Phospholipase A<sub>2</sub>,  
  cardiomyocytes, hypertension 403–407
- Physicochemical factors  
  carbon dioxide, exercise 323–335\*
- Plasma renin activity  
  hyperglycaemia, diabetes 189–195  
  renal nerves, hypertension 287–293
- Platelets  
  recombinant hirudin, intracoronary  
  thrombosis 363–368  
  sodium/hydrogen exchange rate, diabetes 13–19
- Policy on clinical research  
  Spain 147–148
- Polymerase chain reaction  
  enterovirus, chronic fatigue syndrome 295–300
- Postprandial haemodynamics  
  cardiac transplant 473–483  
  meal composition 269–276
- Postprandial metabolism  
  insulin resistance 409–415
- Posture  
  sympathetic activity 345–355
- Power spectrum  
  skin microcirculation, autonomic tone 345–355
- Pregnancy  
  angiotensin receptors, myometrium 499–505  
  nitric oxide 493–497
- Probucol  
  acute tobacco smoking 517–523
- Prostacyclin  
  atrial natriuretic peptide, mean blood  
  pressure 87–89
- Prostaglandin G/H synthase  
  gene expression, endotoxaemia 301–306
- Protein  
  postprandial haemodynamics 269–276
- Protein requirements  
  urea kinetics 215–225
- Protein turnover  
  muscle, starvation 457–466  
  post-absorptive state, bed rest 73–75
- Proteinuria  
  angiotensin-converting enzyme inhibition,  
  nephrosis 393–401
- Proteoglycans  
  burns, wound healing 417–425
- Psycho-neuro-immune-endocrine system  
  vascular endothelium, heart failure 321–322
- Reactive oxygen species scavengers  
  lung oedema, hypoxic pulmonary  
  vasoconstriction 47–54
- Renal haemodynamics  
  endothelin-1 385–391
- Renal nerves  
  baroreflex sensitivity, hypertension 287–293
- Renal tubular function  
  dopamine, lithium clearance 511–515
- Renovascular hypertension  
  natriuretic peptides, gene expression 197–204

- Resistance artery  
 Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
- Respiratory sinus arrhythmia  
 heart rate variability 227–234
- Rheology  
 microvascular disease, peripheral neuropathy 183–187
- Salt intake  
 renal nerves, hypertension 287–293
- Scopolamine  
 respiratory sinus arrhythmia 227–234
- Seasonal variation  
 blood pressure 55–60
- <sup>75</sup>SeHCAT test  
 lathosterol, bile acid malabsorption 315–319
- Sepsis  
 cyclo-oxygenase, endotoxaemia 301–306  
 microcirculation 173–182\*
- Sherpas  
 cerebral hypoxia, magnetic resonance 81–85
- Skin microcirculation  
 autonomic tone 345–355
- Small intestine  
 epidermal growth factor, starvation 427–431
- Sodium excretion  
 renal nerves, hypertension 287–293
- Sodium/hydrogen exchange rate  
 diabetes, microalbuminuria 13–19
- Sodium–potassium–chloride co-transport  
 uraemia 3–8
- Sodium, potassium pump  
 uraemia 3–8
- Spain  
 progress in clinical research 147–171
- Spectral analysis  
 heart rate variability, thermoregulation 97–103
- Starvation  
 amino acid turnover, protein turnover 457–466  
 mucosal mass, epidermal growth factor 427–431
- Steatosis  
 alcohol,  $\beta$ -oxidation 307–313
- Strength loss  
 muscle damage, eccentric exercise 119–125
- Streptozotocin  
 diabetes mellitus, nitric oxide 379–384
- Stress  
 fatty acids, coronary heart disease 243–253\*
- Superoxide dismutase  
 lung oedema, hypoxic pulmonary vasoconstriction 47–54
- Sympathetic nerves  
 sodium retention, hypertension 287–293
- Temperature  
 blood pressure 55–60
- Theophylline  
 asthma, perception 227–234
- Thermoregulation  
 heart rate variability, spectral analysis 97–103
- Thrombin  
 recombinant hirudin, intracoronary thrombosis 363–368
- Thrombosis  
 thrombin, recombinant hirudin 363–368
- Tissue nutrition  
 sepsis 173–182\*
- Tobacco smoke inhalation  
 probucol 517–523
- Tocopherol  
 acute tobacco smoking, probucol 517–523
- Total exchangeable body sodium  
 heart failure, diuretics 31–36
- Tracer  
 protein turnover, muscle 457–466
- Transitional cell carcinoma  
 angiogenesis, basic fibroblast growth factor 127–133
- Tumour necrosis factor- $\alpha$   
 fulminant hepatic failure 77–80
- Tumour necrosis factor soluble receptor  
 fulminant hepatic failure 77–80
- Uraemia  
 sodium, potassium pump 3–8
- Urea  
 protein turnover, bed rest 73–75
- Urea kinetics  
 protein requirements 215–225
- Urological disease  
 angiogenesis, basic fibroblast growth factor 127–133
- Urothelial carcinoma  
 inflammation, basic fibroblast growth factor 127–133
- Uterine angiotensin receptors  
 pregnancy 499–505
- Vascular endothelium  
 heart failure, psycho–neuro–immune–endocrine system 321–322
- Vascular mechanics  
 definitions 143–146
- Vascular medicine  
 Spain 159–160
- Vascular permeability  
 diabetes, microangiopathy 113–117
- Vascular smooth muscle  
 calcium, ouabain 9–12

- Vascular structure
  - Goldblatt hypertension, angiotensin-converting enzyme inhibitors 21–29
- Vasodilating agents
  - oxygen consumption/delivery relationship 105–111
- Veins
  - nitric oxide, pregnancy 493–497
- Venous *N*<sup>G</sup>-monomethyl-L-arginine pregnancy 493–497
- Venous pooling
  - orthostatic intolerance, autonomic insufficiency 277–285
- Virus infection
  - chronic fatigue syndrome, polymerase chain reaction 295–300
- Wound healing
  - burns, proteoglycans 417–425